Preventing Bioprocessing Data Silos With Unified Data Ecosystems

As the complexity of bioprocessing grows, data-driven decision-making is becoming increasingly important. However, disconnected systems and data silos are barriers to collecting, integrating, and acting on process data. 

Data silos are also limiting the potential of AI and automation in bioprocessing, as these technologies rely on high-quality, accessible data. 

To address fragmented data infrastructure in bioprocessing, new integration approaches are being developed to streamline communication between instruments, laboratory information management systems (LIMS), and manufacturing execution systems (MES). 

Technology Networks spoke with Paul Parsons, the co-founder and chief technology officer of The Server Labs, to find out more about how data silos impact the pharmaceutical pipeline, the challenges of data integration, and strategies to create a truly unified, cloud-based LIMS and MES ecosystem. 

Katie Brighton (KB): How do data silos impact product quality, compliance, and operational efficiency across the pharmaceutical pipeline? 

Paul Parsons (PP): Data silos in pharmaceutical pipelines greatly impact all of these. When quality control (QC) results live in LIMS, and manufacturing execution data lives in MES, with only a thin interface between them, no system holds the complete story of a batch. In traditional on-premises systems, breaking out of these silos is incredibly hard. 

You cannot easily correlate an out-of-trend assay result with the in-process parameters (temperature, mixing time, environmental conditions) that produced it, so root-cause investigations become incredibly difficult across multiple systems. Continued process verification and trending suffer because the data needed to see drift is scattered and time-lagged. Manual transcription between systems adds a further quality risk in its own right. 

Silos are also directly at odds with data integrity expectations (ALCOA+) and with 21 CFR Part 11 / EU Annex 11. Every manual reconciliation or re-keying step is a place where the audit trail can fray. More subtly, silos make it hard to demonstrate a single source of truth and end-to-end traceability to [regulatory] inspectors. You end up proving genealogy by stitching together exports, which inspectors rightly view as a weakness. 

Due to both of these, timescales are impacted in the release timeline (QC and manufacturing data have to be manually collated before disposition), the impossibility of true review-by-exception, longer sample-to-result cycle times, duplicated data entry, and slow technology transfer between sites because there's no portable, contextualized data model to hand over. 

KB: What are the key characteristics of a truly unified, cloud-based LIMS and MES ecosystem, and how does it differ from traditional integrated environments? 

PP: In order to truly answer this question, it’s important to separate the unified cloud LIMS–MES ecosystem into two distinct models.  

One is software as a service (SaaS) from a vendor, such as L7, Sapio, or Labvantage, where everything is available in one platform, but can struggle to integrate with other systems.  

The other is pharmaceutical companies building their own unified data layer and deploying LIMS and MES solutions with hyperscalers such as Amazon Web Services (AWS), Google Cloud Platform, or Azure. This model has the advantage that the data layer can be integrated with other systems.  

For both, the key is having a canonical data model, shared master data (products, materials, specifications, methods, units), and a data lake sitting across both operational systems, so analytics run on contextualized, cross-domain data. Elastic managed cloud services also shift infrastructure and much of the qualification burden onto the platform. 

KB: What are the biggest challenges in integrating LIMS with MES platforms? How can these hurdles be overcome?  

PP: Technical integration is rarely the hardest part; the real challenges are usually organizational and data-related. 

Many laboratories still operate legacy software that predates modern application programming interfaces (APIs). This requires careful modernization using integration layers rather than wholesale replacement.  

The most common technical snag is semantic and master-data mismatch. This happens when the two systems use slightly different names for materials, batches, and units, so a batch in LIMS might not map cleanly with the same batch in the MES. The recommended fix is to run a canonical data model, backed up by master data management, which means the translation happens once, in one place. Luckily, modern cloud systems make this fairly straightforward to achieve.  

This is why it is so essential that companies invest in their data quality; poor master data causes integration failures and can have knock-on effects for the testing and validation processes. Encouragingly, AI testing agents are proving to help reduce the administrative burden here.  

Beyond the technical points, how an organization works can have an impact, especially if it operates in silos. Lab IT and manufacturing IT often report to different managers, whose business areas often have different priorities. So, it is essential that shared governance is a priority; otherwise, the integration will fail, no matter how well designed it is.  

KB: What additional considerations are there when creating a cloud-based data ecosystem in a highly regulated environment? 

PP: Regulated cloud environments require governance to be designed in from the beginning.  

Beyond the standard integration concerns, good practice (GxP) raises several distinct issues. You might inherit a shared-responsibility model with the cloud provider and must qualify the infrastructure accordingly, leveraging the provider's GxP compliance frameworks (AWS, for example, publishes GxP guidance) to avoid re-qualifying what's already attested. You need vendor/supplier qualification of the cloud provider itself as part of your quality system. 

 

When creating a new ecosystem, data integrity, audit trails, and electronic signatures must be non-negotiables from the start, not retrofitted. Data residency and sovereignty (General Data Protection Regulation and country-specific rules, especially where clinical or personally identifiable information is involved) constrain where data and backups can live and must be considered.  

A particularly tricky [consideration] is change management for continuously updated SaaS: a validated environment does not sit comfortably with a vendor pushing updates every few weeks, so you need a defined process for assessing and qualifying releases. 

Finally, retention and archival horizons in pharmaceutical companies are long, sometimes spanning decades, so archival strategy, disaster recovery, and business continuity all need to be carefully designed.  

The cloud-native answer here is that infrastructure-as-code and pre-qualified landing zones turn qualification from a manual, repeated effort into something repeatable and evidenced. 

KB: Can you tell us more about some of the advances in modern cloud architecture, data platforms, and digital ecosystems that are changing the way pharmaceutical companies integrate their data?  

PP: The industry has changed rapidly in the past ten years, and we are in the midst of seeing several shifts converging. The data lakehouse, or data fabric as it is sometimes referred to, collapses the old split between a rigid warehouse and an unstructured lake. This lets structured LIMS/MES records and unstructured data sit in one governed layer, with decoupled storage and compute.  

Event-driven and streaming architectures, such as Kinesis and Managed Streaming for Apache Kafka, have enabled real-time data processing rather than a batch export. Also, data mesh thinking, which is domain-oriented ownership with federated governance, is increasingly relevant for large pharmaceutical players running many sites and product lines in order to avoid a single central bottleneck. 

Infrastructure-as-code is increasingly impacting all highly regulated industries. It makes environments reproducible and pre-qualified, which lowers the validation cost that has historically made pharmaceutical companies slow to adopt cloud.  

On top of the data layer, managed AI/ML services, such as anomaly detection, soft sensors, and predictive quality, are being adopted at pace. And maturing standards, like Allotrope, ISA-95, plus cloud providers' GxP frameworks, are lowering the integration and compliance friction.  

Most excitingly, relatively new advances such as enterprise knowledge fabrics will enable pharmaceutical companies to empower their researchers in ways they haven’t been able to until now by serving as a connective layer between all of their data sources. 

KB: What key metrics should pharmaceutical companies track to measure the success of a Pharma 4.0 integration strategy?  

PP: To ensure your Pharma 4.0 strategy is working, you must use metrics that span business, operational, and regulatory outcomes, being mindful that a gain in one area can mask a problem elsewhere. 

On the operational side, the speed of delivery from the plant is the key indicator and is influenced by laboratory turnaround time, batch release time, overall equipment effectiveness, and manufacturing cycle time. An effective program has strong right-first-time metrics.  

Quality metrics show whether faster also means better. Watch deviation rates, batch rejection rates, and how often you repeat tests, alongside the time it takes to resolve corrective and preventative actions and close out investigations. If the integration is doing its job, all of these should fall.  

The share of data captured automatically, the reduction in manual transcription, and a data quality score tell you how clean and reliable your inputs are. API adoption and data lineage coverage show how well the systems actually connect and how far you can trace any figure back to its source. 

It goes without saying that ensuring compliance is a priority metric. Audit findings, electronic record completeness, and audit trail integrity reveal whether the digital estate holds up to scrutiny. 

Seeing improvements in time-to-market, manufacturing cost per batch, cloud operating efficiency, and wider productivity gains translates the technical work into commercial terms, and AI adoption measured against its business impact shows whether the new tools are earning their place. Ultimately, reductions in time-to-market and manufacturing costs will be the most telling signals of whether the change has worked. 

KB: How can pharmaceutical companies build a unified LIMS-MES ecosystem that not only eliminates data silos today but remains flexible enough to accommodate future technologies, acquisitions, and regulatory requirements?  

 

PP: The organizations that get this right do not build around today's applications. They build around a long-term data architecture, so the systems can change without the foundation having to. 

 

That starts with an API-first approach that avoids proprietary integrations, delivered through a cloud-native platform built on event streaming, managed APIs, and reusable integration services. Underneath sits a canonical data model that establishes consistent enterprise definitions for products, batches, samples, and materials, and a governed cloud data platform that can carry operational reporting, analytics, AI, and regulatory workloads at the same time. 

 

Wherever possible, adopt open standards such as ISA-95, OPC UA, HL7/FHIR where applicable, and modern representational state transfer and event-based APIs, all of which reduce vendor lock-in. 

 

 

Organizations should be prepared for emerging capabilities, such as AI copilots for laboratory and manufacturing teams, autonomous quality investigations, predictive process optimization, digital twins, and agentic workflows.  

 

For companies growing through acquisition, a cloud-native integration layer lets you onboard new sites and systems far more quickly, without forcing an immediate rip-and-replace of the applications they already run.